MCK vs OMCL
MCK: A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes. OMCL: Omnicell empowers healthcare providers to optimize medication management and pharmacy workflows through advanced automation and digital health solutions.
Side-by-side fundamentals
| Metric | MCK | OMCL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $930.25 | $34.83 | |
| Market cap | $108.5B | $1.6B | |
| P/E as of 2026-10-08 | 24.91 | 41.18 | MCK lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | 1.63 | n/a | |
| Net margin | +1.2% | +0.2% | MCK higher |
| Gross margin | +3.6% | +42.5% | OMCL higher |
| Operating margin | +1.5% | +0.4% | MCK higher |
| ROE FY2025, SEC XBRL | n/a | +0.2% | |
| ROA | +5.8% | +0.1% | MCK higher |
| Debt / equity as of 2026-09-03 | 1.29 | 0.13 | OMCL lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.8% | +8.4% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +13.4% | -2.9% | MCK higher |
| Dividend yield as of 2026-09-03 | +0.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | MCK higher |
| Beta as of 2026-09-03 | 0.06 | 0.96 | |
| 1-year return as of 2026-10-08 close | +23.1% | +10.7% | MCK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.